Q-omics provides the consensus-scored ANKRA2 profile across patient tissues and cancer cell-line models. ANKRA2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, ANKRA2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ANKRA2 RNA expression shows 20,790 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight OV, KIRC, and KIRP as cancer lineages where ANKRA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRA2 survival associations across molecular data types. ANKRA2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRA2 RNA expression–survival associations across cancer types. High ANKRA2 expression shows unfavorable associations in OV, DLBC, ESCA and KICH, but favorable associations in BRCA and COAD. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify OV as the clearest survival context for ANKRA2 RNA expression.
This table summarizes ANKRA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ANKRA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRA2 shows lower tumor expression in UCEC and higher tumor expression in KIRC, LIHC, LUAD, CHOL and COAD. The KIRC box plot shows higher ANKRA2 RNA expression in tumor versus normal tissue (log2 FC = +0.560, t-test p < 0.001).
This table shows molecular features associated with ANKRA2 in patient tissues and cancer cell lines. In patient samples, ANKRA2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
